Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 16/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216359 | 0.84 | CXCR5 (0.48) | CXCR5ERAP1GPR132MAPT | |
| SCHEMBL13455706 | 0.83 | CXCR5 (0.47) | CXCR5ERAP1GPR132LPAR1 | |
| SCHEMBL3218256 | 0.82 | CXCR5 (0.49) | CXCR5ERAP1 | |
| SCHEMBL774797 | 0.81 | CXCR5 (0.46) | CXCR5ERAP1GPR132LPAR1 | |
| SCHEMBL774222 | 0.81 | CXCR5 (0.45) | CXCR5ERAP1GPR132LPAR1 | |
| SCHEMBL3214221 | 0.81 | CXCR5 (0.45) | CXCR5ERAP1GPR132LPAR1 | |
| SCHEMBL3207455 | 0.80 | CXCR5 (0.46) | CXCR5ERAP1GPR132LPAR1 | |
| SCHEMBL3220332 | 0.80 | ERAP1 (0.45) | CXCR5ERAP1GPR132LPAR1 | |
| SCHEMBL3214368 | 0.76 | LPAR1 (0.46) | CXCR5ERAP1GPR132LPAR1TP53 | |
| SCHEMBL3216718 | 0.76 | LPAR1 (0.46) | CXCR5ERAP1GPR132LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | CXCR5 3298/4885ERAP1 1699/4885GPR132 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.